Full-Time

Senior Engineer II

Applied Technologies

Posted on 6/13/2026

Moderna

Moderna

5,001-10,000 employees

Develops mRNA-based medicines for health

Compensation Overview

$145.9k - $234.2k/yr

+ Bonus + Equity

No H1B Sponsorship

Norwood, MA, USA

In Person

Category
Biology & Biotech (1)
Required Skills
Data Lake
Python
R
Requirements
  • Ph.D. in Chemical/Biomedical Engineering, Analytical Chemistry, or related discipline with 2+ years of experience, OR M.S. with 8+ years, OR B.S. with 10+ years of relevant industrial experience
  • Hands-on experience developing and implementing Process Analytical Technology (PAT) tools in biopharmaceutical or advanced-therapy manufacturing environments, including sensor specification, installation, and data modelling, and technology transfer
  • Proficient in multivariate data analysis/chemometrics tools (SIMCA, Unscrambler, Python, R) and integration with process automation systems, manufacturing data platforms, and communication protocols (DeltaV, SynTQ, PI AF, OPC UA)
  • Strong understanding of Design of Experiment, current Good Manufacturing Practice, Quality by Design principles, and process validation fundamentals
  • This position is site-based and not eligible for remote work, requiring full-time presence at Moderna’s site
Responsibilities
  • Lead the end-to-end PAT and control strategy, ensuring cross-platform consistency and alignment with Moderna’s digital and automation roadmaps
  • Design, deploy, and maintain spectroscopic, chromatographic, and sensor technologies (e.g., Raman, FTIR, UPLC, rapid sterility, pH/DO micro sensors)
  • Develop chemometric models and real-time dashboards linking process parameters with critical quality attributes
  • Serve as a technical lead on integration of PAT tools into Moderna’s digital ecosystem — including data lakes, electronic batch records (eBR), and advanced process control layers
  • Author and lead technology transfer packages to internal GMP sites and external partners, ensuring seamless comparability and calibration approaches
  • Collaborate with analytical development, MS&T, process automation, digital, engineering, quality, and regulatory teams to ensure PAT solutions are manufacturable and inspection-ready
  • Drive continuous improvement initiatives that reduce cycle times, enhance right-first-time metrics, and improve overall process robustness
  • Mentor staff and champion a scientific culture of curiosity, innovation, and excellence
  • Translate complex analytical and regulatory requirements into integrated solutions aligned with Moderna’s next-gen manufacturing platforms
  • Travel up to 10%, supporting deployment at domestic and international manufacturing sites
Desired Qualifications
  • Demonstrated authorship of Chemistry, Manufacturing and Controls regulatory submissions (Investigational New Drug, Investigational Medicinal Product Dossier, Biologics License Application/Marketing Authorization Application) and participation in health authority interactions related to PAT packages, real-time release testing, and continuous manufacturing
  • Experience with life cycle management, including Good Manufacturing Practice compliance and training
  • Familiarity with expedited regulatory pathways, European Union Good Manufacturing Practice Annex 1, Advanced Therapy Medicinal Product/Cell, Gene, and Tissue (ATMP/CGT) guidances, and relevant International Conference on Harmonisation guidelines (Q8, Q9, Q10, Q12, Q13)
  • Expertise with messenger ribonucleic acid, lipid nanoparticle formulation, or other nucleic acid-based modalities
  • Experience deploying PAT for personalized or small batch therapeutics
  • Lean/Six Sigma Green Belt or higher and a track record of driving efficiency improvements in GMP settings
  • Exceptional communication skills and a collaborative mindset focused on patient impact
  • A desire to make an impact as part of a high-growth, transformational company that is Bold, Relentless, Curious, and Collaborative

Moderna develops medicines built on messenger RNA (mRNA). Its products use mRNA delivered into cells to instruct them to produce specific proteins that can prevent or treat disease, with vaccines being a primary example. In practice, a dose delivers engineered mRNA into the body, cells translate it into a target protein, and the immune system responds or the protein modulates biology to combat disease. Moderna differentiates itself through its focus on building a whole mRNA medicines platform and in-house capabilities for designing, manufacturing, and scaling mRNA therapies, including rapid development and large-scale production. Its goal is to create a new category of medicines based on mRNA that can improve how diseases are discovered, developed, and treated, ultimately improving patient outcomes.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2010

Your Connections

People at Moderna who can refer or advise you

Direct Contacts
Warm Intros
Hiring Managers
University Alumni
Simplify Jobs

Simplify's Take

What believers are saying

  • Three vaccine launches are targeted for 2027-2028, expanding revenue beyond COVID.[1]
  • INTERCEPT-Lynch authorization advances Moderna's oncology-prevention platform in the UK.[1]
  • Moderna maintains 21 pipeline programs and 11 clinical candidates.[1]

What critics are saying

  • Commercial reliance on respiratory vaccines leaves earnings exposed to demand volatility.[1][4]
  • mRNA-4194 remains early-stage, so safety or enrollment setbacks can delay launches.[1]
  • A failed prevention trial would damage Moderna's oncology credibility across the platform.[1]

What makes Moderna unique

  • Moderna builds mRNA medicines that instruct cells to make therapeutic proteins.[4][1]
  • Its platform spans infectious diseases, cancer, and rare diseases.[1][4]
  • mRNA-4194 is Moderna's first investigational cancer-prevention program.[1]

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

Sabbatical Leave

Hybrid Work Options

401(k) Company Match

Parental Leave

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Wellness Program

Mental Health Support

Phone/Internet Stipend

Home Office Stipend

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

1%
BOL News
Jun 11th, 2026
New AI tool detects brain tumors in minutes instead of days.

New AI tool detects brain tumors in minutes instead of days. Heteros demonstrates how AI-enabled digital pathology can revolutionize medical diagnostics. * Web Desk * June 11, 2026 HEIDELBERG, Germany: Scientists have developed an advanced artificial intelligence (AI) system capable of diagnosing brain tumors in just 12 minutes, a dramatic improvement over the current average diagnostic time of about 12 days. Researchers in Heidelberg, Germany, created the AI platform, known as Heteros, which can identify and classify brain tumors with remarkable speed and accuracy. Experts say the technology has the potential to transform the diagnosis of brain cancer worldwide. In recent years, researchers have found that many brain tumors can only be accurately diagnosed through detailed analysis of both their molecular characteristics and microscopic structure. However, such testing is often complex, requires specialized equipment, and can take up to two weeks to produce results. To address these challenges, German scientists developed the AI-powered system to make brain cancer diagnosis faster, simpler, and more accessible. Moritz Gerstung, a researcher at the German Cancer Research Center and one of the leaders of the project, said Heteros demonstrates how AI-enabled digital pathology can revolutionize medical diagnostics. He said the technology allows for rapid and widely accessible diagnostic methods that previously required highly sophisticated technical resources, potentially improving patient care and speeding up treatment decisions for those with brain cancer. Earlier, Researchers at the University of Oxford and pharmaceutical company Moderna have developed an experimental mRNA vaccine aimed at preventing cancer in people at high risk of developing bowel and ovarian cancers. The vaccine, however, has yet to undergo clinical testing and remains in the trial phase. Scientists say the vaccine is based on mRNA technology, which could eventually be used to prevent a wider range of cancers in the future. The research focuses on people with Lynch syndrome, an inherited condition that significantly increases the risk of several cancers, including those affecting the bowel, uterus, ovaries, stomach, pancreas, kidneys and skin.

800Oxygen
Jun 5th, 2026
Browse our complete selection of oxygen concentrators and CPAP machines with free shipping over $99.

Medical Innovation mRNA cancer vaccines 2026: Moderna mRNA-4157 hits 49% recurrence drop. Personalized mRNA cancer vaccines reached Phase 3 in 2026 for melanoma. Results, manufacturing pipeline, and what is next for lung and pancreatic. Dr. Sarah Mitchell (Certified Respiratory Therapist) June 4, 2026 Personalized cancer vaccines arrive. Moderna mRNA-4157 (intismeran autogene) + Keytruda hit its Phase 3 endpoint in 2026, cutting melanoma recurrence 49% vs Keytruda alone. How it works. 1. Tumor biopsy is sequenced 2. AI predicts up to 34 neoantigens unique to the patient 3. An mRNA vaccine encoding those neoantigens is manufactured in ~6 weeks 4. Six monthly doses train T cells to seek-and-destroy residual disease Pipeline 2026. * NSCLC: Phase 2 readout Q4 (BioNTech BNT116) * Pancreatic: Memorial Sloan Kettering personalized vaccine - 50% RFS at 3 years * Renal cell carcinoma: Phase 2 expanded Cost & access. ~$200K per course; Moderna is building a U.S. manufacturing campus in MA targeting 3-week turnaround. Why this matters. For the first time, immunotherapy can be truly individualized, sidestepping the immune-evasion tricks tumors use against checkpoint inhibitors alone. Explore related topics. Ready to shop? Browse its complete selection of oxygen concentrators and CPAP machines with free shipping over $99.

The New York Ledger
May 30th, 2026
Moderna, Inc. (MRNA) presents at Bernstein 42nd Annual Strategic Decisions Conference transcript.

Moderna, Inc. (MRNA) presents at Bernstein 42nd Annual Strategic Decisions Conference transcript. Moderna, Inc. (MRNA) Bernstein 42nd Annual Strategic Decisions Conference May 28, 2026 10:00 AM EDT Company Participants Stéphane Bancel - CEO & Director Conference Call Participants Courtney Breen - Bernstein Institutional Services LLC, Research Division Presentation Courtney Breen Bernstein Institutional Services LLC, Research Division Welcome, everyone. Thank you so much for joining York Ledger for this conversation about Moderna. My name is Courtney Breen. I am the U.S. pharma analyst here at Bernstein. And it is my privilege to have Stephane Bancel here with me, the CEO and Chairman of Moderna. He's been in this role for a decent amount of time as well and has seen Moderna through the ages and through the different eras of the company. So I'm really excited to kind of have an opportunity to dive into kind of Moderna today, where Moderna has come from and where Moderna might be going in the future. I also know that AI is a super important topic for all investors these days. So York Ledger'll be hoping to touch on kind of the impact and potential of AI and drug discovery and kind of in operating some of these businesses. But I do also want to remind you that if there are other topics that I'm not planning on covering that you'd love to have covered in this conversation, please do send them through the Pigeonhole app. You'll find a QR code to be able to send them through. I'll receive them up here and can integrate them into the conversation. So York Ledger want to make this as relevant and as impactful for everyone that's here. Question-and-Answer Session Courtney Breen Bernstein Institutional Services LLC, Research Division But without further ado, Stephane, again, thank you so much for joining York Ledger here today. As I mentioned, you've been leading Moderna for a while, I think, since 2011. It

Logicity
Apr 11th, 2026
The 'V' Word: Why Moderna is Ditching 'Vaccine' for its Cancer Breakthrough.

The 'V' Word: Why Moderna is Ditching 'Vaccine' for its Cancer Breakthrough. Moderna is rebranding its cancer treatment, a promising mRNA-based therapy, to distance itself from vaccine skepticism. This move has sparked debate among medical professionals and raises questions about transparency in clinical trials. Can a simple name change impact the future of cancer treatment? Key takeaways. * Moderna's cancer treatment uses mRNA technology to target specific cancer cells * The company has rebranded its treatment as 'individualized neoantigen therapy' to avoid vaccine skepticism * Medical professionals are divided on the impact of this name change on patient trust and transparency * The Science Behind mRNA Therapy * Moderna and Merck Team Up to Take on Cancer * The 'V' Word Dilemma: Why Moderna is Ditching 'Vaccine' * What the Experts Think: Reactions to Moderna's Rebranding * The Future of Cancer Treatment: Implications and Next Steps * Conclusion: The Road Ahead for Moderna's Cancer Breakthrough The Science Behind mRNA Therapy. Imagine a treatment that can specifically target and kill cancer cells, while leaving healthy cells intact. This is the promise of mRNA therapy, which uses genetic code to program the immune system to attack cancer cells. * mRNA therapy works by sequencing a patient's cancer cells to identify unique molecules, called neoantigens * These neoantigens are then used to create a personalized treatment that instructs the immune system to attack cancer cells Moderna and Merck Team Up to Take on Cancer. Moderna has partnered with Merck to develop its mRNA-based cancer treatment, with impressive results in clinical trials. But as the company moves forward, it's facing a new challenge: vaccine skepticism. * Moderna and Merck have shown that their treatment can halve the chance of cancer recurrence in patients with the deadliest form of skin cancer * The partnership has led to a rebranding of the treatment as 'individualized neoantigen therapy', a move that's sparked debate among medical professionals The 'V' Word Dilemma: Why Moderna is Ditching 'Vaccine' In an effort to distance itself from vaccine controversy, Moderna has stopped using the term 'vaccine' to describe its cancer treatment. But is this move a smart PR strategy, or a recipe for confusion? * Moderna's CEO has said that the rebranding is intended to 'better describe the goal of the program' * However, some medical professionals argue that the change could raise questions about transparency and patient trust What the Experts Think: Reactions to Moderna's Rebranding. Logicity Pvt Ltd spoke to medical professionals and experts in the field to get their take on Moderna's decision to rebrand its cancer treatment. Here's what they had to say. * Some experts, like Ryan Sullivan, a physician at Massachusetts General Hospital, are concerned that the name change could impact patient trust and transparency * Others, like Lillian Siu, a medical oncologist at the Princess Margaret Cancer Centre, believe that the move is a necessary step to avoid vaccine skepticism The Future of Cancer Treatment: Implications and Next Steps. As Moderna moves forward with its rebranded cancer treatment, the company faces a complex landscape of regulatory hurdles, patient trust, and public perception. What does the future hold for this promising therapy? * The success of Moderna's treatment could pave the way for a new generation of cancer therapies * However, the company must navigate a complex regulatory environment and address concerns about transparency and patient trust Conclusion: The Road Ahead for Moderna's Cancer Breakthrough. As the debate around Moderna's rebranding continues, one thing is clear: the future of cancer treatment is complex and multifaceted. What's next for this promising therapy, and how will it impact the lives of patients around the world? * Moderna's treatment has the potential to revolutionize cancer care, but it must navigate a complex landscape of regulatory hurdles and public perception * The company's decision to rebrand its treatment as 'individualized neoantigen therapy' is just the beginning of a larger conversation about transparency, trust, and the future of medicine "Vaccines are maybe a dirty word nowadays, but we still believe in the science and harnessing our immune system to not only fight infections, but hopefully to also fight... cancers" - Kyle Holen, head of Moderna's cancer program "There is some concern that there will be patients who decline to treat their cancer because it is a vaccine" - Ryan Sullivan, physician at Massachusetts General Hospital Final thoughts. As Logicity Pvt Ltd look to the future of cancer treatment, it's clear that Moderna's rebranding is just the beginning of a larger conversation about transparency, trust, and the role of language in shaping its perceptions of medicine. Will the company's move pay off, or will it spark more controversy? Only time will tell, but one thing is certain: the future of cancer care is complex, multifaceted, and full of promise. Sources & credits. Huma Shazia Senior AI & Tech Writer

MedWatch
Apr 9th, 2026
IO Biotech founder after bankruptcy: "our work is far from wasted"

IO Biotech founder after bankruptcy: "our work is far from wasted" The founder and CEO denies that funds have been wasted. IO Biotech's technology lives on with competitors such as moderna, which, according to Mai-Britt Zocca, has copied the company's core program. 9 April 2026at 15:21 Since its founding in 2015 and up until its recent bankruptcy, investors have poured well over DKK 2bn (USD 313m) into the biotech company IO Biotech, but even though the company has now collapsed, that money has not been wasted, according to founder and CEO Mai-Britt Zocca. Try MedWatch for 14 days - and get access to all content. * Continues as a recurring subscription and is billed annually. Can be terminated after 5 months of subscription with 1 month's notice at the end of a month. Minimum price is up to €539.58 excl. VAT corresponding to 7 months of subscription. Right of withdrawal under the Consumer Contracts Act. Read more here. ** Continues as a recurring subscription for 3 months at a time. Minimum price €286.00 excl. VAT. Can be terminated with 1 month's notice at the end of a 3-month period. Right of withdrawal under the Consumer Contracts Act. Read more here.